Recently, clinical trials of prenylation inhibitor in patients with CHD showed decrease of serum HDV RNA, however, serum HDV RNA and ALT returned to pre-treatment levels after discontinuation of therapy and many of them were intolerable to the combination of Lonafarnib 200 mg or 300 mg twice daily with pegylated IFN-α. This evidence concerns the gene GPT and coronary artery disorder.